Loading...
•
Dec 31, 2021
Sana Q4 2021 Earnings Report
Sana Biotechnology reported financial results for Q4 2021 and provided business updates.
Key Takeaways
Sana Biotechnology reported a cash position of $746.9 million, research and development expenses of $108.5 million, and a net loss of $110.7 million for the fourth quarter of 2021. The company is progressing towards clinical trials for its multiple platforms and expects to file INDs for SC291 and SG295 in 2022.
Cash, cash equivalents, and marketable securities totaled $746.9 million.
Research and development expenses were $108.5 million.
Net loss was $110.7 million, or $0.60 per share.
The company expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022.
Forward Guidance
Sana Biotechnology plans to present data at multiple scientific conferences in 2022 and expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022.
Positive Outlook
- Continued progress in building Sana’s hypoimmune ex vivo platform
- Progressed Sana’s hypoimmune allogeneic CD19-targeted CAR T program, SC291; IND expected as early as this year
- Progressed Sana’s in vivo CAR T program, SG295, utilizing a CD8-targeted fusosome to deliver a CD19-targeted CAR; IND expected as early as this year
- Expanded Sana’s CAR T capability to potentially develop best-in-class, broadly accessible CAR T cell therapies
- Progressed Sana’s stem cell-derived pancreatic beta cell program, SC451, with potential to treat type 1 diabetes
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...